Tradestie Institutional Equity Comparison Engine
NUVB vs RCUS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NUVB Overall Edge
NUVB Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nuvation Bio Inc. (NUVB) driven by superior Growth & Margin, Momentum & Technical while RCUS counters with relative strength in Options & Structure. Fundamentally, NUVB trades at N/M Forward P/E with -61.2% operating margin (+242.6% YoY revenue) versus RCUS at N/M Forward P/E and -475.0% operating margin (-65.4% YoY). In options structure, NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro) against RCUS sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
NUVB N/M vs RCUS N/M Fwd P/E
Growth & Margin Winner
NUVB
Op Margin -61.2% vs -475.0% ยท YoY +242.6% vs -65.4%
Momentum & Technical Winner
NUVB
1Y -46.9% vs -22.8% ยท 52W Pos 2% vs 0%
Options & Structure Winner
RCUS
BREAKDOWN (26th %ile IV) vs BREAKDOWN (11th %ile IV)
NUVB
NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap
$1.3B
1M Return
-19.15%
1Y Return
-46.85%
Forward P/E
N/M
Unified AI Score
61.0 / 100
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
RCUS
NYSE
Arcus Biosciences, Inc.
Pharmaceutical Preparations
$15.62
-1.01% 1D
Market Cap
$2.3B
1M Return
-19.32%
1Y Return
-22.75%
Forward P/E
N/M
Unified AI Score
48.9 / 100
HOLD
Tech 44.0
Fund 56.0
Flow 70.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NUVB -46.85%
RCUS -22.75%
Spread: +24.1 pp (RCUS Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NUVB Revenue | RCUS Revenue | NUVB Op. Margin | RCUS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $10M | N/A | -656.8% | RCUS |
| FY2019 | N/A | $10M | N/A | -591.4% | RCUS |
| FY2020 | N/A | $80M | N/A | -159.0% | RCUS |
| FY2021 | N/A | $380M | N/A | 14.1% | RCUS |
| FY2022 | N/A | $40M | N/A | -736.8% | RCUS |
| FY2023 | N/A | $40M | N/A | -918.9% | RCUS |
| FY2024 | $10M | $50M | -7527.3% | -647.1% | RCUS |
| FY2025 | $60M | $30M | -338.7% | -1169.7% | NUVB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NUVB | RCUS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.3B | $2.3B | Larger Scale | RCUS |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +242.6% | -65.4% | Higher Growth | NUVB |
| Operating Margin (TTM) Profitability | -61.2% | -475.0% | Higher Margin | NUVB |
| Net Profit Margin Profitability | -67.4% | 0.0% | Higher Margin | RCUS |
| Return on Equity (ROE) Capital Efficiency | -49.1% | -114.1% | Higher ROE | NUVB |
| 52-Week Range Position Momentum | 2% ($4โ$10) | 0% ($16โ$32) | Stronger Trend | NUVB |
| Beta / 30D Volatility Risk Regime | 1.52ฮฒ ยท 55% Vol | 1.39ฮฒ ยท 54% Vol | Lower Realized Risk | RCUS |
| Unified Institutional Score Composite Signal | 61.0 / 100 (BUY) | 48.9 / 100 (HOLD) | Higher Composite | NUVB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NUVB vs RCUS Buy Guide
NUVB
BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
26th %ile
IV Regime
Balanced (25thโ60th %ile)
RCUS
BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
11th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NUVB nor RCUS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.